Literature DB >> 27979336

Past, present and future of cutaneous lymphomas.

Lorenzo Cerroni1.   

Abstract

Primary cutaneous lymphomas represent a broad group of diseases with different clinical, histopathological, phenotypic, molecular, and prognostic features. All cutaneous lymphomas share the same tropism of neoplastic lymphocytes for the skin, but precise classification is paramount for proper management of the patients. Primary cutaneous lymphomas are classified according to the schemes proposed by the European Organization for Research and Treatment of Cancer (EORTC)-Cutaneous Lymphomas Task Force together with the World Health Organization (WHO) in 2005, and the WHO classification of 2008 with the 2016 update. The recognition of organ-based lymphomas, including cutaneous lymphomas, reflects a shift in the approach to lymphoproliferative disorders, and represents one of the major advances in the WHO classification of hematological tumors. Future studies should be aimed at shedding light on the many grey areas of cutaneous lymphomas (particularly the diagnosis and nomenclature of early mycosis fungoides and variants), and at gathering more data on the disorders that are still listed as provisional entities in the WHO classification.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alopecia mucinosa; Cutaneous B-cell lymphoma; Cutaneous T-cell lymphoma; Cutaneous lymphoma; Lymphomatoid papulosis; Mycosis fungoides; Parapsoriasis; Pityriasis lichenoides; Sèzary syndrome

Mesh:

Year:  2016        PMID: 27979336     DOI: 10.1053/j.semdp.2016.11.001

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  1 in total

1.  Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B Cell Lymphoma and Acute Myeloid Leukemia.

Authors:  Junichi Miyatake; Hiroaki Inoue; Kentarou Serizawa; Yasuyoshi Morita; J L Espinoza; Hirokazu Tanaka; Takahiro Shimada; Yoichi Tatsumi; Takashi Ashida; Itaru Matsumura
Journal:  Intern Med       Date:  2018-01-11       Impact factor: 1.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.